OncoMed Pharmaceuticals Inc. (OMED) Jumps 7.01% on January 05

Equities Staff |

OncoMed Pharmaceuticals Inc. (OMED) was among the biggest gainers on the Russell 2000 for Tuesday January 05 as the stock popped 7.01% to $23.51, representing a gain of $1.54 per share. Some 309,240 shares traded hands on 2,198 trades, compared with an average daily volume of 157,590 shares out of a total float of 30.11 million. The stock opened at $22.40 and traded with an intraday range of $23.98 to $22.17.

After today's gains, OncoMed Pharmaceuticals Inc. reached a market cap of $707.86 million. OncoMed Pharmaceuticals Inc. has had a trading range between $29.83 and $13.33 over the last year, and it had a 50-day SMA of $21.14 and a 200-day SMA of $21.91.

OncoMed Pharmaceuticals Inc is a clinical development-stage biopharmaceutical company focused on discovering and developing novel protein therapeutics targeting cancer stem cells, or CSCs.

OncoMed Pharmaceuticals Inc. is based out of Redwood City, CA and has some 108 employees. Its CEO is Paul J. Hastings.

For a complete fundamental analysis analysis of OncoMed Pharmaceuticals Inc., check out Equities.com’s Stock Valuation Analysis report for OMED. To see the latest independent stock recommendations from Equities.com’s analysts, visit our Research section.

The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It's maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.

Russell's indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It's a simple approach that gives a broad, unbiased look at the small-cap market as a whole.

For more news on the financial markets, go to Equities.com. Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Comments

Emerging Growth

Beleave Inc.

Beleave Inc is a biotech company. The Company is engaged in the production of medical marijuana under the Marihuana for Medical Purposes Regulations outlined by Health Canada.

Private Markets

Uber

Uber connects riders with safe, reliable, convenient transportation providers at a variety of price-points in cities around the world. Uber makes money from charging their drivers 20% of the fare…

Initial State

Initial State is an Internet of Things (IoT) data analytics & data management platform company. We turn sensor and event data into information that matters by making it easy to…